In the BioHarmony Drug Report Database

"Preview" Icon

Cenegermin-bkbj

Oxervate (cenegermin) is a protein pharmaceutical. Cenegermin was first approved as Oxervate on 2017-07-06. It is used to treat keratitis in the USA. It has been approved in Europe to treat keratitis. The pharmaceutical is active against beta-nerve growth factor. In addition, it is known to target tumor necrosis factor receptor superfamily member 16.

 

Trade Name

 

Oxervate
 

Common Name

 

cenegermin
 

ChEMBL ID

 

CHEMBL4297852
 

Indication

 

keratitis
 

Drug Class

 

Growth factors

Image (chem structure or protein)

Cenegermin-bkbj structure rendering